Canadians withdraw lumiracoxib▼ (Prexige®)
admin October 12th, 2007
The NPCi blog documents the recent withdrawal of lumiracoxib▼ (Prexige®) in Canada and argue that:
The concern about lumiracoxib’s▼ potential for rare but serious, even fatal liver reactions must feature in prescribing decisions about the drug, along with the increased risk of thrombotic events seen with all coxibs (note that all coxibs are now contraindicated for people with established ischaemic heart disease, cerebrovascular disease and peripheral artery disease, and individual risk assessment is appropriate for patients with risk factors for cardiovascular events)